Brief: Hansoh Pharmaceutical Says HS-20152 Injection Receives Clinical Trial Approval From NMPA
23/03/2026 01:08
March 23 (Reuters) - Hansoh Pharmaceutical Group Company Ltd 3692.HK: HS-20152 INJECTION RECEIVES CLINICAL TRIAL APPROVAL FROM NMPA OF CHINA Further company coverage: 3692.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hansoh Pharmaceutical
See all newsHansoh Pharmaceutical jumps most in 8 weeks on Roche tie-up
Deals of the day-Mergers and acquisitions
Factbox: Major drugmakers turn to China for licensing deals
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion (updated)
China's Hansoh Pharma strikes drug deal with Roche worth over $15 billion